Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382485 | 0.76 | CYP19A1 (0.47) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2350719 | 0.71 | CYP19A1 (0.69) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2354499 | 0.70 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1041969 | 0.68 | CYP19A1 (0.76) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1912921 | 0.67 | CYP19A1 (0.74) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL8845131 | 0.66 | CYP19A1 (0.63) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3285331 | 0.66 | CYP19A1 (0.55) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL5597190 | 0.65 | CYP19A1 (0.67) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Nitric Acid SCHEMBL9845213 | 0.65 | CYP19A1 (0.81) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL5792445 | 0.65 | CYP19A1 (0.47) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748986-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076794-A1 | Hyperaldosteronism | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076794-A1 | Hyperaldosteronism | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076794-A1 | Hyperaldosteronism | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2005118541-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076794-A1 | Hyperaldosteronism | REN, NR3C2, CYP11B2 | CYP19A1 122/4885CYP11B2 3/4885CYP11B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.